CoChat

A review of the history, properties, and use of the immunomodulatory compound lenalidomide

Zeldis, Jerome B., Knight, Robert, Hussein, Mohamad, Chopra, Rajesh, Muller, George · 2011 · Annals of the New York Academy of Sciences
Cited by 77

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Abstract

Lenalidomide (REVLIMID™), an immunomodulatory compound targeting both cancer cells and their microenvironment, has substantial activity in several difficult‐to‐manage hematological malignancies. In previously treated multiple myeloma, lenalidomide produces high‐quality responses combined with sustained disease control. Recently, several randomized studies have demonstrated a clinical benefit of continuous lenalidomide treatment in newly diagnosed multiple myeloma. In many patients with refractory anemia associated with lower risk myelodysplastic syndromes and a 5q chromosome deletion, lenalidomide leads to transfusion independence, considerably improving quality of life. It has a manageable safety profile, and its oral formulation reduces the burden on patients. Several phase III trials are ongoing in other indications currently underserved by conventional therapy, such as chronic lymphocytic leukemia, non‐Hodgkin's lymphoma, and prostate cancer. Several early‐stage studies are exploring lenalidomide alone and in combination across different hematological malignancies, solid tumors, and immune‐related disorders.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1749-6632.2011.05974.x

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 77

Metadata

Authors
Zeldis, J. B., Knight, R., Hussein, M., Chopra, R., & Muller, G.
Venue
Annals of the New York Academy of Sciences
Publisher
Wiley
Published
2011-03
Volume
1222
Issue
1
Pages
76-82
ISSN
  • 0077-8923 (ISSN-L)
  • 1749-6632
OpenAlex
W2166959486
Cited by
77
References
7
FWCI
3.40
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.